Open AccessImpact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study
Author(s) -
Vincenzo Spagnuolo,
Marta Voarino,
Marco Tonelli,
Laura Galli,
Andrea Poli,
Elena Bruzzesi,
Sara Racca,
Nicola Clementi,
Chiara Oltolini,
Moreno Tresoldi,
Patrizia Rovere Querini,
Lorenzo Dagna,
Alberto Zangrillo,
Fabio Ciceri,
Massimo Clementi,
Antonella Castagna
Publication year - 2022
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s369473
Subject(s) - medicine , hazard ratio , proportional hazards model , cohort , covid-19 , pneumonia , multivariate analysis , cohort study , viral load , gastroenterology , immunology , confidence interval , human immunodeficiency virus (hiv) , disease , infectious disease (medical specialty)
Evidence regarding the impact of remdesivir (RDV) on SARS-CoV-2 viral clearance (VC) is scarce. The aim of this study was to compare VC timing in hospitalized COVID-19 patients who did or did not receive RDV.